{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:42:47Z","timestamp":1785526967885,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sanofi R&D"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16222-9","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:44:47Z","timestamp":1780047887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging the evidence gap in trial inclusion with real world safety profile assessment in relapsed\/refractory multiple myeloma patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Rana","family":"Jreich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Loustalot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kahina","family":"Lounaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi","family":"Van de Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoling","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"16222_CR1","unstructured":"U.S. Food and Drug Administration. Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. Silver Spring (MD): FDA; 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies."},{"key":"16222_CR2","unstructured":"U.S. Food and Drug Administration. Enhancing the Diversity of Clinical Trial Populations \u2014 Eligibility Criteria, Enrollment Practices, and Trial Designs: Guidance for Industry. Silver Spring (MD): FDA; 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enhancing-participation-clinical-trials-eligibility-criteria-enrollment-practices-and-trial-designs."},{"key":"16222_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41586-021-03430-5","volume":"592","author":"R Liu","year":"2021","unstructured":"Liu R, Rizzo, Shemra, Whipple S, et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature. 2021;592:629\u201333. https:\/\/doi.org\/10.1038\/s41586-021-03430-5.","journal-title":"Nature"},{"key":"16222_CR4","doi-asserted-by":"publisher","first-page":"104032","DOI":"10.1016\/j.jbi.2022.104032","volume":"127","author":"JR Rogers","year":"2022","unstructured":"Rogers JR, Pavisic J, Casey N, et al. Leveraging electronic health record data for clinical trial planning by assessing eligibility criteria\u2019s impact on patient count and safety. J Biomed Inform. 2022;127:104032. https:\/\/doi.org\/10.1016\/j.jbi.2022.104032.","journal-title":"J Biomed Inform"},{"key":"16222_CR5","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1182\/blood-2023-185175","volume":"142","author":"ZHUKOVSKY WHITE, Joshua","year":"2023","unstructured":"WHITE, Joshua ZHUKOVSKY, Sara CLIFF, Edward R, Scheffer, et al. Prevalence of exclusion criteria in multiple myeloma randomized controlled trials: a systematic review. Blood. 2023;142:2402. https:\/\/doi.org\/10.1182\/blood-2023-185175.","journal-title":"Blood"},{"issue":"3","key":"16222_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1182\/blood.2022018657","volume":"142","author":"B Kanapuru","year":"2023","unstructured":"Kanapuru B, Fernandes LL, Baines A, Ershler R, Bhatnagar V, Pulte E, Gwise T, et al. Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials. Blood J Am Soc Hematol. 2023;142(3):235\u201343. https:\/\/doi.org\/10.1182\/blood.2022018657.","journal-title":"Blood J Am Soc Hematol"},{"key":"16222_CR7","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0164","author":"R Jreich","year":"2024","unstructured":"Jreich R, Zhang H, Meng Z, Wang F. Evaluating the robustness of an AI pathfinder application on eligibility criteria in multiple myeloma trials using real-world data and historical trials. J Comp Eff Res. 2024. https:\/\/doi.org\/10.57264\/cer-2023-0164.","journal-title":"J Comp Eff Res"},{"key":"16222_CR8","doi-asserted-by":"publisher","unstructured":"Birnbaum B, Nussbaum. Nathan and Seidl-Rathkopf, Katharina and Agrawal, Monica and Estevez, Melissa and Estola, Evan and Haimson, Joshua and He, Lucy and Larson, Peter and Richardson, Paul. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv preprint arXiv. 2020:2001.09765. https:\/\/doi.org\/10.48550\/arXiv.2001.09765.","DOI":"10.48550\/arXiv.2001.09765"},{"key":"16222_CR9","doi-asserted-by":"publisher","unstructured":"Ma X, Lura L, Moon S, Adamson, Blythe JS, Baxi, Shrujal S. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.16.20037143.","DOI":"10.1101\/2020.03.16.20037143"},{"key":"16222_CR10","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Bethesda (MD): U.S. Department of Health and Human Services; 2017. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development#ctcae-and-ctep-codes."},{"key":"16222_CR11","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661\u201379. https:\/\/doi.org\/10.1002\/sim.6607.","journal-title":"Stat Med"},{"key":"16222_CR12","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1002\/sim.5705","volume":"32","author":"PC Austin","year":"2013","unstructured":"Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013;32:2837\u201349. https:\/\/doi.org\/10.1002\/sim.5705.","journal-title":"Stat Med"},{"key":"16222_CR13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185362","author":"C Fu","year":"2023","unstructured":"Fu C, et al. Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study. Blood. 2023. https:\/\/doi.org\/10.1182\/blood-2023-185362.","journal-title":"Blood"},{"issue":"9","key":"16222_CR14","doi-asserted-by":"publisher","first-page":"E226","DOI":"10.1002\/ajh.27001","volume":"98","author":"E Kastritis","year":"2023","unstructured":"Kastritis E, Terpos E, Symeonidis A, et al. Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed\/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study. Am J Hematol. 2023;98(9):E226\u20139. https:\/\/doi.org\/10.1002\/ajh.27001.","journal-title":"Am J Hematol"},{"key":"16222_CR15","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3324\/haematol.2011.054015","volume":"97","author":"SY Kristinsson","year":"2012","unstructured":"Kristinsson SY, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012;97:854\u20138. https:\/\/doi.org\/10.3324\/haematol.2011.054015.","journal-title":"Haematologica"},{"issue":"4","key":"16222_CR16","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1111\/bjh.17412","volume":"193","author":"A Kuzume","year":"2021","unstructured":"Kuzume A, Tabata R, Terao T, et al. \u00ab Safety and Efficacy of Daratumumsab in Patients with Multiple Myeloma and Severe Renal Failure \u00bb. Br J Haematol. 2021;193(4):e33\u201336. https:\/\/doi.org\/10.1111\/bjh.17412.","journal-title":"Br J Haematol"},{"key":"16222_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1600-0609.1998.tb01075.x","volume":"61","author":"H Gregersen","year":"1998","unstructured":"Gregersen H, et al. The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance. Eur J Haematol. 1998;61:140\u20134. https:\/\/doi.org\/10.1111\/j.1600-0609.1998.tb01075.x.","journal-title":"Eur J Haematol"},{"key":"16222_CR18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt M, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102:910\u201321. https:\/\/doi.org\/10.3324\/haematol.2016.162693.","journal-title":"Haematologica"},{"key":"16222_CR19","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1182\/blood-2022-166989","volume":"140","author":"A Thet","year":"2022","unstructured":"Thet A, Myint PT, Hadid T. Safety and Tolerability of Anti-CD38 Monoclonal Antibodies (mAb) in Multiple Myeloma. Blood. 2022;140:2552\u201312553. https:\/\/doi.org\/10.1182\/blood-2022-166989.","journal-title":"Blood"},{"key":"16222_CR20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.clml.2021.02.002","volume":"21","author":"C Lim","year":"2021","unstructured":"Lim C, et al. Clin. Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies. Lymphoma Myeloma Leuk. 2021;21:444\u201350. https:\/\/doi.org\/10.1016\/j.clml.2021.02.002.","journal-title":"Lymphoma Myeloma Leuk"},{"issue":"4","key":"16222_CR21","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/ejhf.3209","volume":"26","author":"B Heidecker","year":"2024","unstructured":"Heidecker B, Pagnesi M, et, Thomas F, L\u00fcscher. \u00ab Heart Failure and Respiratory Tract Infection: Cause and Consequence of Acute Decompensation? \u00bb. Eur J Heart Fail. 2024;26(4):960\u201362. https:\/\/doi.org\/10.1002\/ejhf.3209.","journal-title":"Eur J Heart Fail"},{"key":"16222_CR22","doi-asserted-by":"publisher","unstructured":"Joseph P, Lanas F, Roth G et al. 2025. Cardiovascular Disease in the Americas: The Epidemiology of Cardiovascular Disease and Its Risk Factors. The Lancet Regional Health \u2013 Americas 42 (f\u00e9vrier). https:\/\/doi.org\/10.1016\/j.lana.2024.100960.","DOI":"10.1016\/j.lana.2024.100960"},{"key":"16222_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.37616\/2212-5043.1311","volume":"34","author":"B Buck","year":"2022","unstructured":"Buck B, Kellett E, Addison D, Vallakati A. Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS). J Saudi Heart Assoc. 2022;34:134\u201341. https:\/\/doi.org\/10.37616\/2212-5043.1311.","journal-title":"J Saudi Heart Assoc"},{"key":"16222_CR24","doi-asserted-by":"publisher","first-page":"13560","DOI":"10.3390\/ijerph192013560","volume":"19","author":"HY Jang","year":"2022","unstructured":"Jang HY, et al. Carfilzomib\u2019s Real-World Safety Outcomes in Korea: Target Trial Emulation Study Using Electronic Health Records. Int J Environ Res Public Health. 2022;19:13560. https:\/\/doi.org\/10.3390\/ijerph192013560.","journal-title":"Int J Environ Res Public Health"},{"key":"16222_CR25","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.3390\/cancers13205057","volume":"13","author":"E Terpos","year":"2021","unstructured":"Terpos E, et al. Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed\/Refractory Multiple Myeloma: A Prospective Study. Cancers. 2021;13:5057. https:\/\/doi.org\/10.3390\/cancers13205057.","journal-title":"Cancers"},{"issue":"2","key":"16222_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clml.2016.11.009","volume":"17","author":"KD Kistler","year":"2017","unstructured":"Kistler KD, Kalman J, Sahni G, Murphy B, Werther W, Rajangam K, Chari A. Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an obsevational, retrospective, cohort study. Clin Lymphoma Myeloma Leuk. 2017;17(2):89\u201396. https:\/\/doi.org\/10.1016\/j.clml.2016.11.009.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"16222_CR27","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.ahj.2005.07.032","volume":"151","author":"C Berry","year":"2006","unstructured":"Berry C, et al. The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J. 2006;151:1313\u201321. https:\/\/doi.org\/10.1016\/j.ahj.2005.07.032.","journal-title":"Am Heart J"},{"key":"16222_CR28","doi-asserted-by":"publisher","unstructured":"Liu Y, Hou H-A, Qiu H, Tang C-H. Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan. Sci Rep. 2020;14393. https:\/\/doi.org\/10.1038\/s41598-020-71243-z.","DOI":"10.1038\/s41598-020-71243-z"},{"key":"16222_CR29","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1038\/s41598-025-87838-3","volume":"15","author":"JM Jung","year":"2025","unstructured":"Jung JM, et al. \u00abRisk of second primary malignancies among survivors of cutaneous melanoma: A nationwide population-based study in the Republic of Korea\u00bb. Sci Rep. 2025;15:3541. https:\/\/doi.org\/10.1038\/s41598-025-87838-3.","journal-title":"Sci Rep"},{"key":"16222_CR30","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1093\/jnci\/djs233","volume":"104","author":"J Chubak","year":"2012","unstructured":"Chubak J, Yu O, Pocobelli G, et al. Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Natl Cancer Inst. 2012;104:931\u201340. https:\/\/doi.org\/10.1093\/jnci\/djs233.","journal-title":"J Natl Cancer Inst"},{"key":"16222_CR31","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1097\/MLR.0b013e318289c3fb","volume":"53","author":"JL Whyte","year":"2015","unstructured":"Whyte JL, Engel-Nitz NM, Teitelbaum A, et al. An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data. Med Care. 2015;53:e49\u201357. https:\/\/doi.org\/10.1097\/MLR.0b013e318289c3fb.","journal-title":"Med Care"},{"key":"16222_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/CCI.20.00165","volume":"5","author":"KARIMI Yasmin","year":"2021","unstructured":"Yasmin KARIMI, Douglas HBLAYNEY, Allison WKURIAN. Development and use of natural language processing for identification of distant cancer recurrence and sites of distant recurrence using unstructured electronic health record data. JCO Clin Cancer Inf. 2021;5:469\u201378. https:\/\/doi.org\/10.1200\/CCI.20.00165.","journal-title":"JCO Clin Cancer Inf"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16222-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16222-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16222-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:07:13Z","timestamp":1785521233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16222-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16222"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16222-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used deidentified data, which does not constitute human subjects research according to the Common Rule and national regulations. As such, it did not require ethics approval or patient informed consent. Interviews was not applicable to this study. Study was performed on de-identified data in compliance with applicable regulations and no efforts were made to re-identify individuals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not appliacable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rana Jreich, Zhaoling Meng and Helgi Van De Velde are employees of Sanofi and hold shares and\/or stock options in Sanofi.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"907"}}